Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholestatic syndromes.

Michael Trauner1, James L Boyer

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Karl-Franzens University, School of Medicine, Graz, Austria.

Current Opinion in Gastroenterology
|February 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Utility of Elastography in Discriminating Stages of Liver Fibrosis and Risk Stratification in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.

Alimentary pharmacology & therapeutics·2026
Same author

Conjugated bile acid-driven CD14<sup>+</sup>CD16<sup>+</sup> monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis.

JHEP reports : innovation in hepatology·2025
Same author

Liver Lymphatic Dysfunction as a Driver of Fibrosis and Cirrhosis Progression.

bioRxiv : the preprint server for biology·2025
Same author

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatology communications·2024
Same author

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

Cells·2024
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Understanding liver transport mechanisms improves cholestatic liver disease treatment. Molecular insights enhance diagnosis and management of hereditary cholestasis and its complications.

Area of Science:

  • Hepatology and molecular biology
  • Gastroenterology
  • Liver disease research

Background:

  • Cholestatic liver diseases stem from impaired hepatobiliary transport.
  • Hereditary cholestatic syndromes and extrahepatic manifestations present diagnostic and therapeutic challenges.
  • Primary biliary cirrhosis, primary sclerosing cholangitis, and drug-induced cholestasis are significant clinical concerns.

Purpose of the Study:

  • To elucidate cellular and molecular mechanisms of hepatobiliary transport.
  • To improve understanding of cholestatic liver disease pathogenesis.
  • To identify molecular bases for hereditary cholestatic syndromes and extrahepatic manifestations.

Main Methods:

  • Review of recent scientific literature on hepatobiliary transport.

Related Experiment Videos

  • Analysis of molecular and cellular mechanisms in liver diseases.
  • Synthesis of findings on pathogenesis, diagnosis, and treatment.

    • Main Results:

    • Enhanced understanding of hepatobiliary transport function and regulation.
    • Identification of molecular underpinnings for hereditary cholestatic syndromes.
    • New insights into pathogenesis of extrahepatic cholestasis, such as pruritus.

    Conclusions:

    • Advances in understanding hepatobiliary transport aid in managing cholestatic liver diseases.
    • Molecular identification improves diagnosis and management of hereditary conditions.
    • Novel treatment strategies emerge for extrahepatic manifestations of cholestasis.